$ACIU News
Last published 1w ago
- 1w agoACIUAC Immune Third Quarter 2026 Financial and Corporate UpdateGlobeNewswireAC Immune Third Quarter 2026 Financial and Corporate Update Positive clinical and regulatory progress achieved across wholly-owned pipeline ACI-7104 received FDA Fast Track designation, Investigational New Drug (IND)
- 1mo agoACIUAC IMMUNE - CONFERENCE CALL & LIVE WEBCAST - AC IMMUNE SAEarnings Call TranscriptsHello, and a warm welcome to everyone joining this call, where we will discuss the results of part one of the vaccine phase two trial, covering both the 18-month treatment period and the six-month safety follow-up. Today
- 2mo agoACIUAC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764GlobeNewswireAC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome Preliminary data showed ACI-19764 was safe and well tolerated
- 3mo agoACIUAC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)GlobeNewswireAC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD) Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational
- 3mo agoACIUAC Immune First Half 2026 Financial and Corporate UpdateGlobeNewswireAC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline,
- 4mo agoACIUAC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026GlobeNewswireAC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering
- 4mo agoACIUAC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s DiseaseGlobeNewswireAC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three Alzheimer’s disease
- 5mo agoACIUAC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's DiseaseGlobeNewswireAC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104Planned extension of Part 1 will assess
- 5mo agoACIUAC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALSGlobeNewswireAC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients with amyotrophic
- 6mo agoACIUAC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGMGlobeNewswireAC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenureBoard Chair, Martin Zügel, MD, to be appointed interim
- 6mo agoACIUAC Immune First Quarter 2026 Financial and Corporate UpdatesGlobeNewswireAC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expected in H2
- 6mo agoACIUAC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's DiseaseGlobeNewswireAC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 million
- 7mo agoACIUAC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with LillyGlobeNewswireAC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for targeting intracellular Tau and significant progress
- 8mo agoACIUAC Immune Reports Full Year 2025 Financial Results and Provides a Corporate UpdateGlobeNewswireAC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson's diseaseNLRP3
- 8mo agoACIUAC Immune Announces Upcoming Industry Symposium on Parkinson's Disease and Presentation at AD/PD™ 2026GlobeNewswireAC Immune Announces Upcoming Industry Symposium on Parkinson's Disease and Presentation at AD/PD™ 2026 AC Immune to host symposium highlighting Precision Prevention approach to Parkinson's
- 8mo agoACIUAC Immune Initiates Phase 1 Clinical Trial of NLRP3 InhibitorGlobeNewswireAC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitorNLRP3 inhibitors are a major new class of compounds linked to a broad
- 11mo agoACIUAC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's DiseaseGlobeNewswireAC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease Results show, for the first time, that targeting underlying a-syn pathology with an active
- 1y agoACIUAC Immune to Present at the Jefferies 2025 London Healthcare ConferenceGlobeNewswireAC Immune to Present at the Jefferies 2025 London Healthcare Conference Lausanne, Switzerland, November 11, 2025 -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision
- 1y agoACIUAC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate UpdateGlobeNewswireAC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Sharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small molecule programs
- 1y agoACIUAC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory BoardGlobeNewswireAC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board Brings substantial expertise in development of first-in-class disease-modifying therapies in dementia across multiple novel
- 1y agoACIUFirst Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision MedicineGlobeNewswireFirst Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine Aggregated TDP-43 is a pathological hallmark of neurodegenerative
- 1y agoACIUPeer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicineGlobeNewswire
- 1y agoACIUAC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash RunwayGlobeNewswireAC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce reduction of
- 1y agoACIUAC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateGlobeNewswireAC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical
- 1y agoACIUAC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateGlobeNewswireAC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive
- 1y agoACIUAC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's DiseaseGlobeNewswireAC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn)
- 1y agoACIUAC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025GlobeNewswireAC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company's industry-leading pipeline of active
- 1y agoACIUAC Immune Reports Full Year 2024 Financial Results and Provides a Corporate UpdateGlobeNewswireAC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of
- 1y agoACIUAC Immune to Participate in Upcoming Investor ConferencesGlobeNewswireAC Immune to Participate in Upcoming Investor Conferences Lausanne, Switzerland, March 4, 2025 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative
- 1y agoACIUAC IMMUNE SA et al. - Appeal, AffirmedUS Patent Trial and Appeal Board
- 1y agoACIUAC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndromeGlobeNewswireAC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related
- 1y agoACIUAC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's DiseaseGlobeNewswireAC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein antibody levels on
- 1y agoACIUAC Immune to Present at the Jefferies 2024 London Healthcare ConferenceGlobeNewswireAC Immune to Present at the Jefferies 2024 London Healthcare Conference Lausanne, Switzerland, November 13, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for
- 2y agoACIUAC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateGlobeNewswireAC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease (PD) on track to report interim safety and immunogenicity dataPrescreening
- 2y agoACIUAC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's DiseaseGlobeNewswireAC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone
- 2y agoACIUAC Immune's PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative ConditionsGlobeNewswireAC Immune's PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions PI-2620 is in Phase 3 development in Alzheimer's disease by AC Immune's partner, LMIThis Fast Track
- 2y agoACIUAC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateGlobeNewswireAC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Announced exclusive option and license agreement with Takeda for ACI-24.060 on May 13 for $100 million upfront and total potential
- 2y agoACIUAC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024GlobeNewswireAC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 morADC combines proprietary brain-penetrant small molecule Morphomers®
- 2y agoACIUAC Immune's ACI-35.030 (now "JNJ-2056") Granted FDA Fast Track Designation for Alzheimer's DiseaseGlobeNewswireAC Immune's ACI-35.030 (now "JNJ-2056") Granted FDA Fast Track Designation for Alzheimer's Disease Treatment of first randomized person with preclinical AD expected this quarterPhase 2b ReTain trial is fully funded
- 2y agoACIUAC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024GlobeNewswireAC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer's Association International
- 2y agoACIUAC Immune to Present at the Jefferies Global Healthcare Conference in June 2024GlobeNewswireAC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering the development of
- 2y agoACIUAC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateGlobeNewswireAC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for option exercise and
- 2y agoACIUTAKAC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's DiseaseGlobeNewswireAC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease Takeda to receive exclusive option to license global rights to ACI-24.060, a
- 2y agoACIUTAKTYO:4502AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's DiseaseBusiness Wire− Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer's disease progression − AC Immune to receive upfront
- 2y agoACIUAC Immune Reports Full Year 2023 Financial Results and Provides a Corporate UpdateGlobeNewswireAC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease
- 2y agoACIUAC Immune Announces Upcoming Presentations at AD/PD™ 2024GlobeNewswireAC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024)Andrea Pfeifer, Ph.D., CEO to lead AC
- 2y agoACIUAC Immune to Regain Global Rights to Crenezumab and SemorinemabGlobeNewswireAC Immune to Regain Global Rights to Crenezumab and Semorinemab Company's strategy is focused on advancing the Phase 2 development of its three active immunotherapiesActive immunotherapy now considered to be the optimal
- 2y agoACIUAC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseasesGlobeNewswireAC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases ABATE Phase 1b/2 AD trial of ACI-24.060 completed enrollment of cohorts 1 and 2 and is expected to
- 2y agoACIUAC Immune Announces Pricing of Underwritten Offering of Common SharesGlobeNewswireAC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (NASDAQ:ACIU) (the "Company" or "AC Immune"), a clinical-stage biopharmaceutical company
- 2y agoACIUAC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b TrialGlobeNewswireAC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition